Evidence map›Paper›PMID 31753901›Full record

Observational studyBMJ open2019

Renin-angiotensin system blocker use and the risk of acute kidney injury after colorectal cancer surgery: a population-based cohort study.

Charlotte Slagelse, H Gammelager, Lene Hjerrild Iversen, Kathleen D Liu, Henrik Toft Sørensen, Christian F Christiansen

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Charlotte SlagelseDepartment of Clinical Epidemiology, Aarhus Universitetshospital, Aarhus N, Denmark csjh@clin.au.dk.ORCID 0000-0002-0879-9836
H GammelagerDepartment of Clinical Epidemiology, Aarhus Universitetshospital, Aarhus N, Denmark.
Lene Hjerrild IversenDepartment of Surgery, Aarhus University Hospital, Aarhus N, Denmark.
Kathleen D LiuDepartment of Medicine, Division of Nephrology, School of Medicine, University of California San Francisco, San Francisco, California, USA.
Henrik Toft SørensenDepartment of Clinical Epidemiology, Aarhus Universitetshospital, Aarhus N, Denmark.
Christian F ChristiansenDepartment of Clinical Epidemiology, Aarhus Universitetshospital, Aarhus N, Denmark.
Aarhus University · DKAarhus University Hospital · DKUniversity of California, San Francisco · US

Funding

Advancing acute kidney injury phenotyping using biological and clinical criteriaK24DK113381 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, KATHLEEN D · 2017 to 2021
$915k
NIDDK NIH HHS K24 DK113381
6 · The paper itself

Abstract

objectivesIt is unknown whether preoperative use of ACE inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) affects the risk of acute kidney injury (AKI) after colorectal cancer (CRC) surgery. We assessed the impact of preoperative ACE-I/ARB use on risk of AKI after CRC surgery.

designObservational cohort study. Patients were divided into three exposure groups-current, former and non-users-through reimbursed prescriptions within 365 days before the surgery. AKI within 7 days after surgery was defined according to the current Kidney Disease Improving Global Outcome consensus criteria.

settingPopulation-based Danish medical databases.

participantsA total of 9932 patients undergoing incident CRC surgery during 2005-2014 in northern Denmark were included through the Danish Colorectal Cancer Group Database. OUTCOME MEASURE: We computed cumulative incidence proportions (risk) of AKI with 95% CIs for current, former and non-users of ACE-I/ARB, including death as a competing risk. We compared current and former users with non-users by computing adjusted risk ratios (aRRs) using log-binomial regression adjusted for demographics, comorbidities and CRC-related characteristics. We stratified the analyses of ACE-I/ARB users to address any difference in impact within relevant subgroups.

resultsTwenty-one per cent were ACE-I/ARB current users, 6.4% former users and 72.3% non-users. The 7-day postoperative AKI risk for current, former and non-users was 26.4% (95% CI 24.6% to 28.3%), 25.2% (21.9% to 28.6%) and 17.8% (17.0% to 18.7%), respectively. The aRRs of AKI were 1.20 (1.09 to 1.32) and 1.16 (1.01 to 1.34) for current and former users, compared with non-users. The relative risk of AKI in current compared with non-users was consistent in all subgroups, except for higher aRR in patients with a history of hypertension.

conclusionsBeing a current or former user of ACE-I/ARBs is associated with an increased risk of postoperative AKI compared with non-users. Although it may not be a drug effect, users of ACE-I/ARBs should be considered a risk group for postoperative AKI.

Indexed as

Acute Kidney InjuryAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCohort StudiesColorectal NeoplasmsDatabases, FactualDenmarkDigestive System Surgical ProceduresFemaleHumansHypertensionIncidenceMaleMiddle AgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonistscolorectal cancer surgerypostoperative AKIrenin-angiotensin system blockersrisk

Identifiers

PMID31753901
PMCPMC6887015
OpenAlexW2990370470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.